Abstract
Among the current applications of biomarkers those for drug discovery and development are one of the most important. Biomarkers are used in new approaches to remedy the shortage of new drugs and to the current lengthy and expensive process of drug development. Biomarkers can be used to predict and confirm target binding, to determine mechanism of action of a drug, pharmacokinetics, toxicity, and to monitor disease status, stratify patients, and determine treatment efficacy in clinical trials. The parallel role of biomarkers in the drug discovery process is shown in Fig. 4.1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ashton AE. Quantitative MR in multi-center clinical trials. J Magn Reson Imaging. 2010;31:279–88.
Boudonck KJ, Mitchell MW, Német L, et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol. 2009;37:280–92.
Frueh FW, Amur S, Mummaneni P, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008;28:992–8.
Germain RN. Vaccines and the future of human immunology. Immunity. 2010;33:441–50.
Havenar-Daughton C, Lindqvist M, Heit A, et al. CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A. 2016;113:2702–7.
Heal WP, Wickramasinghe SR, Tate EW. Activity based chemical proteomics: profiling proteases as drug targets. Curr Drug Discov Technol. 2008;5:200–12.
Li Y, Wang L, Ju L, et al. A systematic strategy for screening and application of specific biomarkers in hepatotoxicity using metabolomics combined with ROC curves and SVMs. Toxicol Sci. 2016;150:390–9.
Luo FR, Yang Z, Dong H, et al. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 2005;56:455–64.
Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol. 2008;25:655–64.
McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8:10–6.
Michán C, Ramos JL, Daniels C. Explorative probes and biomarkers, chronic salmonella infections and future vaccines. Microb Biotechnol. 2012;5:1–4.
Munshi R, Johnson A, Siew ED, et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol. 2011;22:165–75.
Ozer JS, Dieterle F, Troth S, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol. 2010;28:486–94.
Pomfret TC, Gagnon JM Jr, Gilchrist AT. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther. 2011;36:1–9.
Rahmoune H, Guest PC. Application of multiplex biomarker approaches to accelerate drug discovery and development. Methods Mol Biol. 2017;1546:3–17.
Salter H, Holland R. Biomarkers: refining diagnosis and expediting drug development - reality, aspiration and the role of open innovation. J Intern Med. 2014;276:215–28.
Sauer JM, Walker EG, Porter AC. The predictive safety testing consortium: safety biomarkers, collaboration, and qualification. J Med Dev Sci. 2015;1:34–45.
van Gool AJ, Henry B, Sprengers ED. From biomarker strategies to biomarker activities and back. Drug Discov Today. 2010;15:121–6.
Van Kersavond T, Nguyen MTN, Verhelst SHL. Synthesis and application of activity-based probes for proteases. Methods Mol Biol. 2017;1574:255–66.
Villanueva J, Nazarian A, Lawlor K, Tempst P. Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Nat Protoc. 2009;4:1167–83.
Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106:4402–7.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this chapter
Cite this chapter
Jain, K.K. (2017). Biomarkers for Drug Discovery and Development. In: The Handbook of Biomarkers. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7431-3_4
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7431-3_4
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7430-6
Online ISBN: 978-1-4939-7431-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)